pre-IPO PHARMA

COMPANY OVERVIEW

FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://fogpharma.com


    CAREER WEBSITE

    https://fogpharma.com/opportunities-at-fogpharma/


    SOCIAL MEDIA


    INVESTORS

    6-dimensions-capital boyu-capital deerfield-management gv horizons-ventures wuxi-apptech


    PRESS RELEASES


    Jun 5, 2023

    FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors


    Mar 30, 2023

    Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer


    Nov 21, 2022

    FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers


    Mar 9, 2022

    FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin


    Nov 22, 2021

    FogPharma Expands Executive Leadership Team


    For More Press Releases


    Google Analytics Alternative